National Pension Service Has $2.84 Million Stock Holdings in Insmed, Inc. $INSM

National Pension Service trimmed its position in Insmed, Inc. (NASDAQ:INSM) by 91.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 26,678 shares of the biopharmaceutical company’s stock after selling 285,203 shares during the quarter. National Pension Service’s holdings in Insmed were worth $2,844,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in INSM. CIBC Private Wealth Group LLC lifted its stake in Insmed by 42.1% during the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 53 shares during the last quarter. Reflection Asset Management bought a new position in shares of Insmed in the 4th quarter valued at $30,000. Raiffeisen Bank International AG bought a new position in shares of Insmed in the 4th quarter valued at $32,000. Larson Financial Group LLC raised its holdings in shares of Insmed by 137.0% during the 4th quarter. Larson Financial Group LLC now owns 256 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 148 shares in the last quarter. Finally, Towarzystwo Funduszy Inwestycyjnych PZU SA acquired a new position in shares of Insmed during the 4th quarter worth $49,000.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Cantor Fitzgerald restated an “overweight” rating and set a $235.00 price objective on shares of Insmed in a research report on Tuesday, July 28th. Truist Financial reiterated a “buy” rating and issued a $195.00 target price (up from $185.00) on shares of Insmed in a research report on Monday, August 10th. Evercore reissued an “outperform” rating and set a $170.00 target price on shares of Insmed in a research note on Friday, August 7th. Royal Bank Of Canada reduced their price target on shares of Insmed from $205.00 to $195.00 and set an “outperform” rating on the stock in a research note on Friday, June 5th. Finally, UBS Group reaffirmed a “buy” rating and set a $172.00 price target on shares of Insmed in a report on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $205.52.

Insider Buying and Selling at Insmed

In other news, insider Michael Smith sold 1,806 shares of the firm’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $95.82, for a total transaction of $173,050.92. Following the completion of the transaction, the insider owned 37,648 shares of the company’s stock, valued at approximately $3,607,431.36. This trade represents a 4.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David R. Brennan sold 25,000 shares of Insmed stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $124.00, for a total transaction of $3,100,000.00. Following the transaction, the director owned 39,238 shares in the company, valued at approximately $4,865,512. This trade represents a 38.92% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 298,753 shares of company stock valued at $38,704,764. 2.10% of the stock is owned by insiders.

Insmed Stock Performance

Shares of INSM stock opened at $129.41 on Monday. The business’s 50-day moving average price is $117.76 and its 200-day moving average price is $124.00. Insmed, Inc. has a 12 month low of $90.39 and a 12 month high of $212.75. The firm has a market capitalization of $28.26 billion, a price-to-earnings ratio of -31.49 and a beta of 0.82. The company has a current ratio of 3.72, a quick ratio of 3.40 and a debt-to-equity ratio of 0.74.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.61. The company had revenue of $425.49 million during the quarter, compared to the consensus estimate of $395.50 million. Insmed had a negative return on equity of 123.94% and a negative net margin of 76.94%.The firm’s revenue was up 296.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.70) earnings per share. Equities research analysts forecast that Insmed, Inc. will post -1.83 EPS for the current year.

Insmed Profile

Insmed Incorporated (NASDAQ: INSM) is a global biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases. The company’s work centers on areas of significant unmet medical need, including pulmonary and infectious diseases, as well as other specialty conditions.

Insmed’s primary commercial product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled antibacterial therapy approved in the United States for adults with refractory Mycobacterium avium complex lung disease as part of a combination antibacterial regimen.